12:00 AM
 | 
Jan 31, 2011
 |  BioCentury  |  Strategy

Selling mouse futures

Ablexis, investors using open licensing model for quick ROI from AlivaMab mouse

The two most popular mouse platforms to discover human antibodies, Abgenix Inc.'s XenoMouse and Medarex Inc.'s HuMAb Mouse, have been licensed only once since Abgenix was acquired by Amgen Inc. in 2005 and Medarex was acquired by Bristol-Myers Squibb Co. in 2009. Ablexis LLC hopes to fill the gap in the marketplace with its next-generation AlivaMab Mouse and a licensing model that provides a quick ROI for its investors.

Ablexis has released few details about its platform. However, CEO Larry Green told BioCentury the company uses bacterial artificial chromosomes (BACs) to generate transgenic mice that have been previously impossible to make.

Unlike yeast artificial chromosomes (YACs), which were used to construct XenoMouse and the HuMAb Mouse, BACs can carry highly repetitive DNA sequences. This enables cloning of not only the human immunoglobulin genes but also the extended DNA sequence that controls their expression. Green says this will allow the AlivaMab Mouse to produce a more robust immune response against a candidate target.

Read the full 814 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >